雷莫西尤单抗联合多西他赛用于铂类化疗联合程序性死亡受体1阻断后晚期非小细胞肺癌的多中心真实世界数据:NEJ051(REACTIVE研究)
这项多中心回顾性研究纳入288例在铂类化疗联合PD-1阻断后二线接受雷莫西尤单抗联合多西他赛的晚期非小细胞肺癌患者,客观缓解率28.8%,中位无进展生存4.1个月,中位总生存11.6个月,作者认为该方案可行。
要点
- 雷莫西尤单抗联合多西他赛二线治疗的客观缓解率为28.8%,疾病控制率为69.8%。
- 中位无进展生存4.1个月,中位总生存11.6个月。
- 非腺癌和PS 2-3是无进展生存更差的独立预后因素。
核心结论
- 作者认为,对于接受过铂类化疗联合PD-1阻断的晚期非小细胞肺癌患者,雷莫西尤单抗联合多西他赛是可行的二线治疗。
研究设计与样本
- 多中心回顾性研究,纳入2017年1月至2020年8月在日本62家机构接受雷莫西尤单抗联合多西他赛作为二线治疗的288例晚期非小细胞肺癌患者。
- 预后分析采用对数秩检验,预后因素分析采用Cox回归分析。
主要发现
- 288例患者中,男性222例(77.1%),年龄<75岁262例(91.0%),有吸烟史237例(82.3%),PS 0-1为269例(93.4%)。
- 腺癌199例(69.1%),非腺癌89例(30.9%)。
- 一线PD-1阻断类型为抗PD-1抗体236例(81.9%),抗PD-L1抗体52例(18.1%)。
- 雷莫西尤单抗联合多西他赛的客观缓解率为28.8%(95%CI 23.7-34.4),疾病控制率为69.8%(95%CI 64.1-75.0)。
- 中位无进展生存4.1个月(95%CI 3.5-4.6),中位总生存11.6个月(95%CI 9.9-13.9)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ramucirumab plus docetaxel (RD) is a promising treatment for previously treated advanced non-small cell lung cancer (NSCLC). However, its clinical significance after platinum-based chemotherapy plus programmed death-1 (PD-1) blockade remains unclear. RESEARCH QUESTION: What is the clinical significance of RD as a second-line treatment after the failure of chemo-immunotherapy in NSCLC? STUDY DESIGN AND METHODS: In this multicentre retrospective study, 288 patients with advanced NSCLC who received RDas second-line therapy after platinum-based chemotherapy plus PD-1 blockade, at 62 Japanese institutions from January 2017 to August 2020, were included. Prognostic analyses were performed using the log-rank test. Prognostic factor analyses were performed using a Cox regression analysis. RESULTS: A total of 288 patients were enrolled: 222 were men (77.1%), 262 were aged <75 years (91.0%), 237 (82.3%) had smoking history and 269 (93.4%) had a performance status (PS) of 0-1. One hundred ninety-nine patients (69.1%) were classified as adenocarcinoma (AC) and 89 (30.9%) as non-AC. The types of PD-1 blockade used in the first-line treatment were anti-PD-1 antibody and anti-programmed death-ligand 1 antibody in 236 (81.9%) and 52 (18.1%) patients, respectively. The objective response rate for RD was 28.8% (95% confidence interval [CI], 23.7-34.4). The disease control rate was 69.8% (95% CI, 64.1-75.0).The median progression free survival and overall survival were 4.1 months (95% CI, 3.5-4.6) and 11.6 months (95% CI, 9.9-13.9), respectively. In a multivariate analysis, non-AC and PS 2-3 were independent prognostic factors for worse progression free survival , while bone metastasis on diagnosis, PS 2-3 and non-AC were identified as independent prognostic factors for poor overall survival. INTERPRETATION: RD is a feasible second-line treatment in patients with advanced NSCLC who had received combined chemo-immunotherapy with PD-1 blockade. CLINICAL TRIAL REGISTRATION NUMBER: UMIN000042333.
引用
- Nakamura A, Yamaguchi O, Mori K, et al. Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). Eur J Cancer. 2023. PMID: 36905770. doi:10.1016/j.ejca.2023.01.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。